Particularly dangerous are the interactions between G. biloba and CYP or other phase II enzymes, which could increase the risk of toxicity in patients treated with drugs, such as valproic acid, trazodone, talinolol, warfarin, etc. It is worth mentioning that the lack of reliable data on the neuroprotective effects of resveratrol and G. biloba challenges their potential beneficial effects in the treatment of neurodegenerative diseases. Here, PPIG is linked to neurodegenerative disease.